R1 Therapeutics Expands Series A to $80.5M for Kidney Disease Drug Development
R1 Therapeutics, a clinical-stage biopharmaceutical company developing therapies for kidney disease, has expanded its Series A financing to $80.5 million with a new investment from Samsara BioCapital. The investment follows…